Andere Sprachen Marinomed Biotech AG

Aktien

A2N9MM

ATMARINOMED6

MARI

Markt geschlossen - Wiener Boerse Andere Börsenplätze 17:35:06 16.04.2024			% 5 Tage	% 1. Jan.
19,35 ^EUR	-0,77 %		-4,68 %	-33,73 %

10:00	Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024
2023	Marinomed Biotech erwägt Partnerschaften und mögliche Übertragung des Carragelose-Portfolios	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AFR: Marinomed Biotech AG: Release of a Financial report	11:31
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets	07:47
AFR: Marinomed Biotech AG: Release of a Financial report	07:46
Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution	15.04.
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico	11.04.
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months	28.03.
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe	26.03.
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations	01.03.
Marinomed Biotech AG announces preliminary revenue for 2023	14.02.
Marinomed Biotech AG with important progress for Carragelose in 2024	07.02.
Marinomed Biotech Considers Partnerships, Potential Transfer of Carragelose Portfolio	18.12.
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio	18.12.
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio	18.12.
Marinomed Biotech Signs Deal With DKSH to Commercialize Carragelose in Four Countries	14.12.
Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent	14.12.
Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development	21.11.
Marinomed Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21.11.
Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume	17.10.23
Marinomed Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17.08.23
Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities	17.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Marinomed Biotech AG

Aktien

A2N9MM

ATMARINOMED6

MARI

Andere Sprachen

Filter